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Abstract
Background: Several systemic inflammatory response (SIR) markers, including platelet-to-lymphocyte ratio (PLR),
neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and albumin-to-globulin ratio (AGR),
have emerged as prognostic markers in various cancers. The aim of this study was to explore the impact of SIR
markers on the survival outcomes of unresectable intrahepatic cholangiocarcinoma (IHC) patients.
Methods: Patients with histologically confirmed, unresectable IHC treated with gemcitabine plus cisplatin (GP)
chemotherapy in a single tertiary hospital from 2012 to 2016 were retrospectively reviewed. Progression-free
survival (PFS) and overall survival (OS) were determined using unadjusted Kaplan-Meier and adjusted Cox-
proportional-hazards analysis. Time-dependent receiver operating characteristic (ROC) analysis was performed to
compare the performance of the SIR markers in predicting OS.
Results: A total of 137 patients received a median of six cycles (interquartile range [IQR], 3–11) of GP chemotherapy
with a median observation time of 9.9 months (range, 1.8–54.7 months). The median PFS and OS of all patients
were 7.8 months and 9.9 months, respectively. Among the SIR markers, high PLR (> 148) and high NLR (> 5) were
associated with a short PFS (Hazard ratio [HR] 1.828, P = 0.006; HR 1.738, P = 0.030, respectively) and short OS (HR
2.332, P < 0.001; HR 2.273, P < 0.001, respectively). Low LMR (< 3.5) and low AGR (< 1.2) were associated with a short
OS (HR 2.423, P < 0.001; HR 1.768, P = 0.002, respectively). In multivariable cox-regression analysis, high PLR (HR
1.766, P = 0.009) and distant lymph node (LN) metastasis (HR 2.085, P = 0.001) were associated with a short PFS.
High PLR (HR 1.856, P = 0.002) was an independent predictor of a short OS, along with distant LN metastasis (HR
1.929; P < 0.001), low LMR (HR 1.691; P = 0.041), and low level of serum albumin (< 3.5 g/dL) (HR 1.632; P = 0.043).
Time-dependent ROC analysis revealed that the area under the curve of PLR for predicting overall survival was
greater than that of NLR, LMR, and AGR at most time points.
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Conclusions: High PLR was an independent prognostic factor of a short PFS and OS in patients with unresectable
IHC receiving GP chemotherapy.
Keywords: Intrahepatic cholangiocarcinoma, Platelet-to-lymphocyte ratio, Overall survival
Background
Intrahepatic cholangiocarcinoma (IHC) is cancer that
originates from epithelial cells of the intrahepatic bile
duct, which accounts for approximately 10% of all cho-
langiocarcinomas [1, 2]. IHC is a rare disease, though its
prevalence varies enormously according to geographic
regions. The incidence rates seem to be increasing glo-
bally. Surgical resection is the only curative treatment;
however, only a minority of patients present with resect-
able disease. The prognosis for IHC is poor, and it re-
mains a challenge to identify prognostic biomarkers to
stratify patients and determine the optimal therapy.
Inflammation is a hallmark of cancer, and the inflamma-
tory response plays an important role in cancer develop-
ment and progression [3]. Several systemic inflammatory
response (SIR) markers, such as platelet-to-lymphocyte
ratio (PLR), neutrophil-to-lymphocyte ratio (NLR),
lymphocyte-to-monocyte ratio (LMR), and albumin-to-
globulin ratio (AGR), have been studied and recognized as
prognostic factors in various cancers. Chronic inflammation
is a key predisposing factor in the development of biliary
tract cancer (BTC) [4], and there are several studies to
evaluate the prognostic impact of SIR markers in BTC.
However, most studies focused on the preoperative values
of these markers in patients with resectable disease. To the
best of our knowledge, there have not been any studies that
have evaluated the prognostic impact of PLR, NLR, LMR,
and AGR together in unresectable IHC patients receiving
systemic chemotherapy.
The aim of the present study was to explore the prog-
nostic value of these SIR markers in patients with unre-
sectable IHC receiving first-line chemotherapy.
Methods
Study subjects
The medical records of patients diagnosed with unresect-
able IHC at Seoul National University Hospital from Janu-
ary 1st, 2012 through December 31st, 2016 were
retrospectively reviewed. All adults aged 20 years or older
with histologically diagnosed IHC, who received gemcita-
bine plus cisplatin (GP) chemotherapy, were included in
the study. Patients who received GP chemotherapy for
only one cycle or received best supportive care or locore-
gional therapy (e.g., transarterial chemoembolization or
radiation therapy) were excluded. Patients with a history
of concomitant malignancy or rheumatic disease within 5
years or missing laboratory values were also excluded
from the study.
Data collection and definitions
Demographic and clinical data were collected, including
age, sex, body mass index, Eastern Cooperative Oncol-
ogy Group performance status (ECOG PS), history of
chronic hepatitis B or C or hepatolithiasis, presence of
cirrhosis, Charlson comorbidity index, presence of con-
comitant malignancies or rheumatic disease, history of
previous biliary drainage, presence of regional or distant
lymph node (LN) metastasis, and site of metastasis. Re-
gional LNs were defined according to the 8th edition of
the AJCC staging manual [5]. Baseline laboratory values
in venous blood, including complete blood cell count,
liver function test, and CA 19–9 levels, were obtained
within a week before the initiation of GP chemotherapy
in patients without evidence of active infection.
PLR and NLR were calculated as the absolute platelet
and absolute neutrophil count divided by the absolute
lymphocyte count, respectively. LMR was calculated as
the absolute lymphocyte count divided by the absolute
monocyte count. AGR was the level of serum albumin
divided by the serum globulin level. Because the optimal
cut-off values for PLR, NLR, LMR, and AGR have not
been established, maximally selected log-rank statistic by
Hothorn and Lausen was used to determine the optimal
cut-off values that represent the maximum difference in
overall survival between groups [6]. R package ‘maxstat’
(https://CRAN.R-project.org/package=maxstat) was used
for this analysis and adjusted p-values were calculated by
the approximation based on an improved Bonferroni in-
equality with an alpha error of 0.05. Patients were strati-
fied by the optimal values, and the clinical characteristics
were compared across groups.
Data on survival outcomes were collected. Progression-
free survival (PFS) was defined as the time from chemo-
therapy initiation until either disease progression or death
due to any cause. Overall survival (OS) was the time from
chemotherapy initiation until death or the last follow-up.
Tumor response was assessed every 6 to 9 weeks accord-
ing to the Response Evaluation Criteria in Solid Tumors
(RECIST), version 1.1 [7]. The response rate was calcu-
lated as the proportion of patients with complete response
or partial response. The disease control rate was defined
as the proportion of patients with complete response, par-
tial response, or stable disease. A minimum time interval
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of 6 weeks was required for patients to be considered eva-
luable for disease control.
Statistical analysis
Data were presented as whole numbers with percentages
for categorical variables and median with interquartile
range (IQR) or mean ± standard deviation for continuous
variables. The Chi-square and Mann-Whitney U tests
were used to compare the categorical and continuous
variables, respectively. Correlation among SIR markers
were determined by the Spearman rank correlation coef-
ficients and Pearson correlation coefficient. Estimates of
the median follow-up period was calculated by the re-
verse Kaplan-Meier method [8]. Estimates of PFS and
OS were calculated using the Kaplan-Meir method. The
log-rank test was used to compare survival outcomes be-
tween the groups. All variables with a univariate P <
0.100 were subjected to multivariable analysis using the
Cox proportional hazards model with backward elimin-
ation. The variance inflation factor was estimated to as-
sess the multicollinearity of the final model. Considering
the collinearity between SIR markers, we conducted fur-
ther multivariable analyses to build separate models.
This time, each SIR marker was assessed separately in
different multivariable models. All reported P-values are
two-sided, and P < 0.05 was considered significant.
Time-dependent receiver operating characteristic (ROC)
curves were created to assess the performance of PLR,
NLR, LMR, and AGR in predicting OS. Time-dependent
ROC curves were estimated using the ‘timeROC’ R pack-
age. All statistical analyses were performed using the
RStudio version 3.44 statistical software package.
Ethical standards
This study was approved by the Institutional Review
Board of Seoul National University Hospital (IRB No. H-
1705-120-855) and conducted in conformity with the
Declaration of Helsinki.
Results
Clinical characteristics of the study population
A total of 251 patients were diagnosed with unresectable
IHC at Seoul National University Hospital from January
1st, 2012 through December 31st, 2016. Of these 251 pa-
tients, 31 patients who received best supportive care
only, 17 patients who received locoregional therapy, and
16 patients who received chemotherapeutic agents other
than GP were excluded from the study. Among the
remaining 187 patients who received GP chemotherapy,
22 patients received only one cycle of GP chemotherapy,
Fig. 1 Flow chart of patient enrollment
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seven patients had a history of concomitant malignancy
or rheumatic disease, and 21 patients had missing la-
boratory data. These 50 patients were also excluded
from the study. The remaining 137 patients were in-
cluded in the study (Fig. 1).
The clinical features of the 137 patients are summa-
rized in Table 1. The median follow-up period by the re-
verse Kaplan-Meier estimates was 35.4 months (95% CI,
34.9 months – not reached). The median observation
time for all patients was 9.9 months (range, 1.8–54.7
months). The median number of GP chemotherapy cy-
cles patients received was 6 cycles (IQR, 3–11 cycles).
The median PFS was 7.8 months (95% CI, 6.3–9.8
months), and the median OS was 9.9 months (95% CI,
8.6–12.0 months) (Fig. 2). Among the 135 patients
(98.5%) with measurable disease, the best overall re-
sponses included a partial response in 23 patients
(17.0%), stable disease in 81 patients (60.0%), progressive
disease in 27 patients (20.0%), and not assessable in four
patients (3.0%), resulting in an overall response rate of
17.0% and disease control rate of 77.0%. Three patients
(2.2%) with initial metastatic IHC underwent conversion
surgery after GP chemotherapy with R0 resection
achieved in two of these patients. Second-line chemo-
therapy after GP treatment failure was given to 71
patients (52.6%) and included fluoropyrimidine-based
combination therapy (e.g. FOLFIRI [5-fluorouracil and
irinotecan], iFAM [infusional 5-fluorouracil, doxorubi-
cin, and mitomycin-C], XP [capecitabine and cis-
platin]) for 45 patients (32.8%), fluoropyrimidine
monotherapy for 17 patients (12.4%), and clinical tri-
als for nine patients (6.6%). Palliative radiation ther-
apy was administered in 13 patients (9.5%) and site of
radiation included bone metastases for 11 patients
(8.0%), portal vein tumor thrombosis for one patient
(0.7%), and brain metastases for one patient (0.7%).
None of the patients received transarterial chemoem-
bolization or radioembolization.
Table 1 Baseline characteristics of all patients (N = 137)
Variable No. (%) or median (IQR)




BMI 23.4 (22.0, 25.3)
ECOG Performance status
0 64 (46.7%)
≥ 1 73 (53.3%)
Chronic hepatitis B 21 (15.3%)
Chronic hepatitis C 4 (2.9%)
Hepatolithiasis 17 (12.4%)
Liver cirrhosis 15 (10.9%)
Child-Pugh class A 12 (8.8%)
Child-Pugh class B 3 (2.2%)
Diabetes mellitus 25 (18.2%)
Charlson Commorbidity Index
0 87 (63.5%)
≥ 1 50 (36.5%)
Biliary drainage 15 (10.9%)
Tumor size, cm 7.0 (5.0, 9.9)
Major vascular invasion 89 (65.0%)
Hilar invasion 16 (11.7%)
Liver metastasis 55 (40.1%)




Distant lymph node metastasis 90 (65.7%)
Number of metastatic sites
0 36 (26.3%)
1 59 (43.1%)
≥ 2 42 (30.7%)
Baseline laboratory findings
White blood cell count, cells/μL 8060 (6700, 9440)
Neutrophil count, cells/μL 5606 (4126, 6751)
Lymphocyte count, cells/μL 1612 (1346, 2029)
Monocyte count, cells/μL 633 (509, 801)
Hemoglobin, g/dL 12.6 ± 1.7
Platelet count, 103 cells/μL 237 (185, 281)
Albumin, g/dL 4.0 (3.6, 4.2)
Globulin, g/dL 3.2 (3.0, 3.6)
Total bilirubin, mg/dL 0.7 (0.5, 0.9)
ALP, IU/L 139 (98, 245)
AST, IU/L 34 (24, 51)
Table 1 Baseline characteristics of all patients (N = 137)
(Continued)
Variable No. (%) or median (IQR)
ALT, IU/L 26 (17, 44)
CA 19–9, U/mL 266 (27, 4280)
Platelet-to-lymphocyte ratio 133 (110, 186)
Neutrophil-to-lymphocyte ratio 3.4 (2.3, 4.4)
Lymphocyte-to-monocyte ratio 2.5 (2.1, 3.2)
Albumin-to-globulin ratio 1.2 ± 0.3
Abbreviations: IQR Interquartile range; BMI Body mass index; ECOG Eastern
Cooperative Oncology Group; ALP Alkaline phosphatase; AST Aspartate
aminotransferase; ALT Alanine aminotransferase; CA 19–9 Carbohydrate
antigen 19–9;
Data regarding hemoglobin and albumin-to-globulin ratio are presented as
mean ± standard deviation
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Relationships between SIR markers
There was a strong correlation between PLR, NLR, and
LMR as follows: PLR and NLR (Spearman’s rho = 0.61, P <
0.001), PLR and LMR (Spearman’s rho = − 0.46, P < 0.001),
and NLR and LMR (Spearman’s rho = − 0.67, P < 0.001).
AGR was associated with LMR (Pearson correlation coeffi-
cient = 0.21, P = 0.016), but there was no significant
association with PLR (P = 0.514) or NLR (P = 0.358)
(Supplementary Figure 1).
Comparisons between groups according to optimal cut-
off values
The optimal cut-off values for the SIR markers were
148 for PLR (P < 0.001), 5.0 for NLR (P = 0.020), 3.5
for LMR (P < 0.001), and 1.2 for AGR (P = 0.025)
(Supplementary Figure 2). Patients were stratified
into groups according to these values. The high PLR
group (N = 63) had significantly lower albumin levels
than the low PLR group (N = 74) (P = 0.030)
(Table 2). There were no other significant differences
in the clinical characteristics between the high and
the low PLR groups. The clinical characteristics of
patients, according to NLR, LMR, and AGR, are
summarized in Supplementary Table 1. Patients with
high NLR (N = 28), low LMR (N = 110), and low
AGR (N = 72) had lower albumin levels compared to
those with low NLR (N = 109), high LMR (N = 27),
and high AGR (N = 65) (P = 0.011, P = 0.012, and
P < 0.001, respectively). The high NLR and low AGR
groups had a higher proportion of poor performance
status (ECOG PS ≥ 1) than the low NLR and high
AGR groups (P = 0.018 and P = 0.035, respectively).
The high LMR and low AGR groups had higher
number of metastatic sites than the low LMR and
high AGR groups (P = 0.001 and P = 0.031, respecti-
vely).The low AGR group had a higher proportion of
patients with distant LN metastasis compared to the
high AGR group (P < 0.001).
Association of SIR markers and survival outcomes
The median PFS was significantly different between
the high and low PLR groups (6.0 vs. 8.6 months; P =
0.006) (Fig. 3a). A significant difference was also ob-
served in the median OS for these groups (8.0 vs.
13.4 months; P < 0.001) (Fig. 3b). Similarly, the high
and low NLR groups had significantly different me-
dian PFS (4.0 vs. 8.6 months; P = 0.030) and OS (6.7
vs. 11.7 months; P < 0.001). The low LMR group had
a significantly shorter OS compared to the high LMR
group (9.1 vs. 19.1 months; P < 0.001); however, the
difference between the median PFS of these two
groups was not statistically significant (6.8 vs. 9.9
months; P = 0.087). Similarly, the low AGR group had
a significantly shorter OS compared to the high AGR
group (8.7 vs. 13.2 months; P = 0.002), but the differ-
ence in the median PFS between these groups was
not statistically significant (6.5 vs. 9.6 months; P =
0.368). The time-dependent ROC analysis revealed
that the area under the curve of PLR for predicting
overall survival was greater than that of NLR, LMR,
and AGR at most time points (Fig. 4).
Predictive factors for PFS
The results of the univariate and multivariable analyses
for PFS are shown in Table 3. Multivariable analysis,
which was performed using variables with a univariate
P < 0.100, showed that high PLR (> 148) and distant LN
metastasis were associated with a short PFS (Hazard ra-
tio [HR] 1.766 [95% CI, 1.155–2.703], P = 0.009; HR
2.085 [95% CI, 1.329–3.272], P = 0.001, respectively).
When SIR markers were assessed separately in multivar-
iable models, high PLR (> 148) was associated with a
short PFS (HR 1.766, P = 0.009), while high NLR (> 5)
Fig. 2 Progression-free survival (2a) and overall survival (2b) of all patients
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and low LMR (< 3.5) were not (HR 1.638 [95% CI,
0.995–2.696], P = 0.052; HR 1.583 [95% CI, 0.963–
2.603], P = 0.070, respectively). (Supplementary Table 2).
Predictive factors for OS
The results of the univariate and multivariate analyses
for OS are shown in Table 4. Multivariable analysis
showed that high PLR (> 148) (HR, 1.856 [95% CI,
1.266–2.723]; P = 0.002), low LMR (< 3.5) (HR 1.691
[95% CI, 1.023–2.797]; P = 0.041), distant LN metastasis
(HR 1.929 [95% CI, 1.305–2.851]; P < 0.001), and low
level of serum albumin (< 3.5 g/dL) (HR, 1.632 [95% CI,
1.017–2.618]; P = 0.043) were independent predictive
factors of a short OS, after adjusting for alkaline phos-
phatase and ECOG PS. The highest variance inflation
factor was 1.13, suggesting no significant multicollinear-
ity between the variables in the final model. When SIR
markers were assessed separately in multivariable
models, high PLR (> 148), high NLR (> 5), low LMR (<
3.5), respectively remained as an independent predictor
Table 2 Clinical characteristics of patients according to PLR
Variable PLR ≤148 (N = 74) PLR > 148 (N = 63) P value
Age, yr 64 (58, 73) 64 (54, 69) 0.247
Sex 1.000
Male 45 (60.8%) 38 (60.3%)
Female 29 (39.2%) 25 (39.7%)
BMI 23.7 (22.2, 25.7) 23.0 (22.0, 24.5) 0.119
ECOG Performance status 1.000
0 35 (47.3%) 29 (46.0%)
≥ 1 39 (52.7%) 34 (54.0%)
Liver cirrhosis 10 (13.5%) 5 (7.9%) 0.443
Diabetes mellitus 15 (20.3%) 10 (15.9%) 0.658
Charlson Commorbidity Index 0.595
0 45 (60.8%) 42 (66.7%)
≥ 1 29 (39.2%) 21 (33.3%)
Biliary drainage 6 (8.1%) 9 (14.3%) 0.379
Tumor size, cm 7.2 (5.4, 10.0) 7.0 (4.5, 9.6) 0.246
Major vascular invasion 53 (71.6%) 36 (57.1%) 0.112
Hilar invasion 9 (12.2%) 7 (11.1%) 1.000
Liver metastasis 27 (36.5%) 28 (44.4%) 0.440
Extrahepatic organ metastasis 38 (51.4%) 37 (58.7%) 0.489
Distant lymph node metastasis 47 (63.5%) 43 (68.3%) 0.688
Number of metastatic sites 0.090
0 10 (13.5%) 2 (3.2%)
1 27 (36.5%) 23 (36.5%)
≥ 2 37 (50.0%) 38 (60.3%)
Baseline laboratory findings
Neutrophil count, cells/μL 5288 (3768, 6403) 5792 (4663, 7231) 0.063
Lymphocyte count, cells/μL 1935 (1547, 2271) 1377 (1119, 1623) < 0.001
Monocyte count, cells/μL 637 (509, 808) 629 (506, 756) 0.837
Platelet count, 103 cells/μL 199 (163, 255) 261 (224, 303) < 0.001
Total bilirubin, mg/dL 0.7 (0.6, 0.9) 0.7 (0.5, 0.9) 0.979
ALP, IU/L 129 (93, 225) 164 (115, 259) 0.074
Albumin, g/dL 4.0 (3.7, 4.2) 3.8 (3.5, 4.1) 0.030
CA 19–9, U/mL 652.5 (44.6, 4830.0) 183.4 (16.1, 2955.0) 0.211
Abbreviations: PLR Platelet-to-lymphocyte ratio; BMI Body mass index; ECOG Eastern Cooperative Oncology Group; ALP Alkaline phosphatase; CA 19–9
Carbohydrate antigen 19–9
Data are presented as no. (%) or median (interquartile range)
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of short OS (HR 2.182 [95% CI, 1.512–3.150], P < 0.001;
HR 1.714 [95% CI, 1.063–2.762], P = 0.027; HR 2.199
[95% CI, 1.367–3.538], P = 0.001, respectively) (Supple-
mentary Table 3).
Discussion
This study is the first to evaluate the association of PLR,
NLR, LMR, and AGR together with PFS and OS in pa-
tients with unresectable IHC. We found that high PLR
(> 148) was an independent prognostic factor of a short
PFS and OS in patients with unresectable IHC receiving
GP chemotherapy. Time-dependent ROC analysis re-
vealed that the area under the curve of PLR for predict-
ing overall survival was greater than that of the other
inflammatory markers (i.e., NLR, LMR, or AGR) at most
time points.
SIR markers, including PLR, NLR, LMR, and AGR,
have been investigated for an association with the prog-
nosis of BTC. Studies on the association of PLR and sur-
vival outcomes in BTC patients are relatively scarce and
mostly only included patients undergoing surgical resec-
tion [9] [10]. Cho et al. [11] reported that high NLR
Fig. 3 Progression-free survival (3a) and overall survival (3b) according to PLR. a: P = 0.005, b: P < 0.001 (log-rank test)
Fig. 4 Time-dependent ROC analysis for PLR, NLR, and LMR according to overall survival
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Table 3 Univariable and multivariable Cox proportional hazard analysis of factors associated with progression free survival
Univariable Multivariable
HR (95% CI) P HR (95% CI) P
Age 0.148
≤ 65 1






≥ 1 1.139 (0.767–1.692)
Charlson Commorbidity index 0.697
0 1
≥ 1 1.084 (0.722–1.626)
Chronic hepatitis B 0.155
No 1
Yes 1.497 (0.934–2.320)










≤ 7 cm 1
> 7 cm 0.838 (0.558, 1.258)
Vascular invasion 0.379
No 1
Yes 0.830 (0.548, 1.257)
Hilar invasion 0.181
No 1




Extrahepatic organ metastasis 0.280
No 1
Yes 1.246 (0.836–1.856)
Distant lymph node metastasis 0.001 0.001
No 1 1
Yes 2.135 (1.361–3.348) 2.085 (1.329–3.272)
Number of metastatic sites
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(≥3.8) and high PLR (≥121) were independent predictors
of a short OS for patients with advanced BTC, including
IHC, extrahepatic cholangiocarcinoma, gallbladder can-
cer, and ampulla of Vater cancer. In our study, high PLR
(> 148), but not high NLR (> 5), was an independent pre-
dictor of a short PFS and OS in patients with advanced
IHC. The discrepancies might be due to the different
study populations of the two studies. In the previous
study, the distribution of PLR varied according to
tumour origin (P = 0.003). There has been accumulating
evidence indicating extreme molecular and biological
heterogeneity in BTC, according to the anatomical loca-
tion of the tumour [12, 13]. Therefore, it is reasonable to
assume that the SIR markers might have different prog-
nostic impacts depending on the cancer type. Another
study that included only patients with advanced IHC
reported that high NLR (> 2.8) and high PLR (> 128.3)
were associated with a short PFS or OS by univariate
analysis, but not multivariable analysis [14]. The reason
for this difference is not clear; however, the different
cut-off values might be one explanation. Because opti-
mal cut-off values for PLR and NLR have not been
established, the previous study chose median values
as cut-off values, while we selected cut-off points that
showed maximal differences in OS. In addition, the
previous study did not investigate the impact of LMR
but explored the association of the modified Glasgow
Prognostic Score, which is based on the level of albu-
min and C-reactive protein. There have not been any
studies that have evaluated LMR in advanced IHC.
However, in advanced gallbladder cancer, our group
recently reported that a high monocyte to lymphocyte
Table 3 Univariable and multivariable Cox proportional hazard analysis of factors associated with progression free survival
(Continued)
Univariable Multivariable
HR (95% CI) P HR (95% CI) P
0 1
1 2.567 (1.064–6.194) 0.036
≥ 2 3.422 (1.467–7.985) 0.004
Total bilirubin 0.336
≤ 1.5 x ULN 1
> 1.5 x ULN 0.611 (0.224–1.666)
Alkaline phosphatase 0.765
≤ 1.5 x ULN 1
> 1.5 x ULN 1.066 (0.703–1.616)
Albumin 0.050
< 3.5 g/dL 1.725 (1.001–2.975)
≥ 3.5 g/dL 1
CA 19–9 0.818
≤ 37 U/mL 1
> 37 U/mL 0.955 (0.643–1.417)
PLR 0.006 0.009
≤ 148 1 1
> 148 1.828 (1.193–2.800) 1.766 (1.155–2.703)
NLR 0.030
≤ 5 1
> 5 1.738 (1.056–2.859)
LMR 0.087
< 3.5 1.538 (0.939–2.520)
≥ 3.5 1
AGR 0.368
< 1.2 1.200 (0.807–1.786)
≥ 1.2 1
Abbreviations: ECOG Eastern Cooperative Oncology Group; CA 19–9 Carbohydrate antigen 19–9; PLR Platelet-to-lymphocyte ratio; NLR Neutrophil-to-lymphocyte
ratio; LMR, lymphocyte-to-monocyte ratio; AGR Albumin-to-globulin ratio
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Table 4 Univariable and multivariable Cox proportional hazard analysis of factors associated with overall survival
Univariable Multivariable
HR P HR P
Age 0.512
≤ 65 1




ECOG PS 0.090 0.092
0 1 1
≥ 1 1.355 (0.953–1.926) 1.372 (0.949–1.984)
Charlson Commorbidity index 0.730
0 1
≥ 1 1.066 (0.742–1.530)
Chronic hepatitis B 0.246
No 1
Yes 1.328 (0.822–2.144)










≤ 7 cm 1
> 7 cm 0.799 (0.564, 1.132)
Vascular invasion 0.346
No 1
Yes 0.841 (0.587, 1.206)
Hilar invasion 0.752
No 1




Extrahepatic organ metastasis 0.108
No 1
Yes 1.332 (0.939–1.889)
Distant lymph node metastasis < 0.001 < 0.001
No 1 1
Yes 1.906 (1.309–2.775) 1.929 (1.305–2.851)
Number of metastatic sites
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ratio (> 0.24) and high PLR (> 108) were associated
with poor survival [15].
The exact mechanisms by which PLR predicts survival
outcomes in cancer patients are not clear. However, there
are plausible mechanisms to explain how thrombocytosis
and lymphopenia are associated with poor prognosis in
cancer patients. The association between platelets and
cancer has been studied since 1865 when Trousseau first
described thrombosis in gastric cancer [16]. Tumour cells
are known to activate platelets and stimulate platelet ag-
gregation. Activated platelets can mediate cancer cell
growth and angiogenesis [17]. They can also directly pro-
tect circulating tumour cells from natural killer cell-
mediated lysis, which promotes metastatic dissemination
[18]. In experimental mouse models, the induction of
thrombocytopenia reduced the rate of metastasis, while
reconstitution with human platelets increased the number
of metastases in vivo [19, 20]. Clinical studies have shown
that thrombocytosis is associated with poor prognosis in
several cancers, including breast, lung, colon, gastric, and
ovarian cancer [21]. The lymphocyte is a key mediator of
immunosurveillance and antitumor immunity [22]. A low
number of lymphocytes could be responsible for a weak
immune response against cancer cells.
Data on the association of PLR and OS according to
the stage of BTC are insufficient; however, studies con-
ducted in other solid cancers suggest that the signifi-
cance of PLR is greater for metastatic disease than for
early-stage disease [23, 24]. Furthermore, PLR values
were greater in metastatic disease than in early-stage dis-
ease. In our study, PLR was not associated with the level
of CA 19–9 or organ/lymph node metastasis and the
Table 4 Univariable and multivariable Cox proportional hazard analysis of factors associated with overall survival (Continued)
Univariable Multivariable
HR P HR P
0 1
1 2.753 (1.292–5.864) 0.009
≥ 2 2.987 (1.434–6.221) 0.003
Total bilirubin 0.604
≤ 1.5 x ULN 1
> 1.5 x ULN 1.209 (0.590–2.480)
Alkaline phosphatase 0.008 0.125
≤ 1.5 x ULN 1 1
> 1.5 x ULN 1.632 (1.138–2.340) 1.337 (0.923–1.939)
Albumin 0.001 0.043
< 3.5 g/dL 2.268 (1.424–3.610) 1.632 (1.017–2.618)
≥ 3.5 g/dL 1 1
CA 19–9 0.530
≤ 37 U/mL 1
> 37 U/mL 1.118 (0.790–1.583)
PLR < 0.001 0.002
≤ 148 1 1
> 148 2.332 (1.610–3.378) 1.856 (1.266–2.723)
NLR < 0.001
≤ 5 1
> 5 2.273 (1.471–3.512)
LMR < 0.001 0.041
< 3.5 2.423 (1.516–3.875) 1.691 (1.023–2.797)
≥ 3.5 1 1
AGR 0.002
< 1.2 1.768 (1.236–2.528)
≥ 1.2 1
Abbreviations: ECOG Eastern Cooperative Oncology Group; CA 19–9 Carbohydrate antigen 19–9; PLR Platelet-to-lymphocyte ratio; NLR Neutrophil-to-lymphocyte
ratio; LMR Lymphocyte-to-monocyte ratio; AGR Albumin-to-globulin ratio
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number of metastatic sites. These findings might be
due to the small number of patients with advanced
disease that were included in this study. Further
studies comprising a large number of patients with
different stages and tumour burden are needed to
investigate the association of PLR and other clinical
variables in IHC.
Not surprisingly, there were strong correlations be-
tween SIR markers. PLR was positively associated with
NLR and negatively associated with LMR. This SIR
marker was also negatively associated with albumin, but
there was no significant association with AGR. Albumin
has been classically known to reflect nutritional status;
however, recent studies have shown that the level of al-
bumin is decreased during inflammation, regardless of
nutritional status [25]. Globulin plays an important role
in immunity and inflammation. Because levels of both
albumin and globulin are easily influenced by factors,
such as dehydration or oedema, AGR has been suggested
and explored as a prognostic factor in several cancers
[26]. In the present study, the serum albumin levels and
AGR were significantly associated with distant LN me-
tastasis, which was the strongest independent predictive
factor of PFS and OS. Low AGR did not remain as an in-
dependent prognostic factor of OS after multivariable
analysis, which might be due to its association with the
presence of distant LN metastasis and ECOG PS.
There are several limitations to the current study. First,
it was a single-centre, retrospective study, and the number
of patients comprising the study population was small.
Due to the rarity of IHC, the number of IHC patients is
limited in a single-centre design. However, multicentre
studies have a pitfall that stems from different blood pro-
cessing techniques between laboratories. Second, the
current study included only patients who received at least
two cycles of GP. We believed that this approach could
minimize the potential confounding effect that might re-
sult from different anticancer therapies. Thus, the results
may not be generalizable to other populations, including
patients receiving non-GP chemotherapy, concurrent che-
moradiation therapy, locoregional therapy, or best sup-
portive care only. Third, the dichotomous cut-off value of
the SIR markers might be arbitrary. Currently, optimal
cut-off values for the SIR markers have not been estab-
lished, and they vary between studies. We chose to use di-
chotomized cut-offs because previous studies utilizing
such cut-offs have shown a better association between
PLR and overall survival than those with three risk cat-
egories [23]. The optimal cut-off values in the present
study, which were determined using a statistical method,
were similar to those of the previous studies [26–29].
Nevertheless, they warrant further validation in large, pro-
spective studies since outcome-oriented approach to select
cut-off value might result in overfitting.
Conclusions
High PLR (> 148) might be a useful prognostic factor of
a short PFS and OS in patients with unresectable IHC
who received first-line chemotherapy. Low LMR (< 3.5)
was an independent prognostic factor of a short OS.
Low AGR was associated with the presence of distant
LN metastasis, which was an independent prognostic
factor of a short PFS and OS. Further studies are needed
to validate the prognostic impact of SIR markers in
unresectable IHC.
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